Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR)

Toni K. Choueiri; Yousef Zakharia; Sumanta K. Pal; Judit Kocsis; Russell K. Pachynski; Alexandr Poprach; Andrew B. Nixon; Yingmiao Liu; Mark D. Starr; Jing Lyu; Kouros Owzar; Mollie deShazo; Primo N. Lara; Lajos Géczi; Thai H. Ho; Meghara Walsh; Bonne J. Adams; Liz Robertson; Mohamed Darif; Charles P. Theuer; Neeraj Agarwal

doi:10.1002/onco.13777

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

The combination of carotuximab with axitinib did not demonstrate additional efficacy over single agent axitinib in patients with mccRCC who progressed following one or more prior VEGF inhibitor treatment.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Choueiri et al. (2021) studied this question.

synapsesocial.com/papers/69dbdcec40b636d1dda3bf78 https://doi.org/10.1002/onco.13777

View Full Paper

Ask AI

Bookmark

Share

Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR)

Ask about this paper

Abstract

Discussion

Cite This Study

Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR)

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading